



ASX Announcement
30 May 2023

ENTITLEMENT OFFER TIMETABLE UPDATE

Optiscan Imaging Limited (ASX: OIL) provides the following updated timetable in relation to its pro rata entitlement offer of one (1) fully paid ordinary share (**Share**) for every three (3) Shares (**Offer**) as announced to ASX on 30 May 2023. The Offer will raise up to \$16,698,816 by the issue of up to 208,735,201 Shares in the capital of the Company at an issue price of \$0.08 per Share.

The timetable below has been updated to reflect dates in accordance with the ASX listing Rules:

Lodgement of Prospectus with the ASIC	Pre-market open on Tuesday, 30 May 2023
Lodgement of Prospectus and Appendix 3B with ASX	Pre-market open on Tuesday, 30 May 2023
Ex date	Thursday, 1 June 2023
Rights start trading	Thursday, 1 June 2023
Record Date for determining Entitlements (5:00pm WST)	Friday, 2 June 2023
Offer opening date, Prospectus sent out to Shareholders and Company announces this has been completed	Wednesday, 7 June 2023
Rights stop trading	Thursday, 22 June 2023
Securities quoted on a deferred settlement basis	Friday, 23 June 2023
Last day to extend the Closing Date	Monday, 26 June 2023
Closing Date as at 5:00pm WST*	Thursday, 29 June 2023
Announcement of results of issue	Thursday, 6 July 2023
Issue of the Shares under the Offer	Thursday, 6 July 2023
Quotation of Shares issued under the Offer**	Friday, 7 July 2023

All dates and times are indicative only and subject to change. The Company reserves the right to withdraw the Offer or amend all or any of these dates and times without notice, subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For investor queries, please contact:

Dr. Camile Farah

Chief Executive Officer & Managing Director

Optiscan Imaging Ltd

E: cfarah@optiscan.com

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com